On February 9, 2022 Kuraray reported that Business Results for the Fiscal Year Ended December 31, 2021 (Press release, Kuraray, FEB 9, 2022, https://pdf.irpocket.com/C3405/OMfg/YY6Q/Ybo2.pdf [SID1234607875])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Consolidated Financial Results for Fiscal 2021 (January 1, 2021 to December 31, 2021)
(1) Consolidated Operating Results (Percentage changes displayed for net sales, operating income, ordinary income and net income attributable to owners of the parent are comparisons with the corresponding period of the previous fiscal year.)
(2) Consolidated Financial Position
(3) Consolidated Cash Flows

2. Dividends

3. Forecasts of Consolidated Financial Results for the Fiscal Year Ending December 31, 2022 (January 1, 2022 to December 31, 2022)

1. Unconsolidated Results for Fiscal 2021 (January 1, 2021 – December 31, 2021) (Percentages displayed for net sales, operating income, ordinary income and net income attributable to owners of the parent are comparisons with the previous fiscal year.)

(1) Unconsolidated Operating Results
(2) Unconsolidated Financial Position